Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-09-11
2000-09-26
Fonda, Kathleen K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3152
Patent
active
061243035
ABSTRACT:
A method for inhibiting neoplastic cells and related conditions by exposing them to 9-substituted 2-(2-n-alkoxyphenyl)purin-6-one compounds.
REFERENCES:
patent: 3031450 (1962-04-01), Fischer et al.
patent: 3161654 (1964-12-01), Shen
patent: 3322755 (1967-05-01), Roch et al.
patent: 3517005 (1970-06-01), Cronin et al.
patent: 3594480 (1971-07-01), Cronin et al.
patent: 3647858 (1972-03-01), Hinkley et al.
patent: 3654349 (1972-04-01), Shen et al.
patent: 3780040 (1973-12-01), Schnettler et al.
patent: 3812127 (1974-05-01), Cronin et al.
patent: 3819631 (1974-06-01), Broughton et al.
patent: 3920636 (1975-11-01), Takahasi et al.
patent: 4001237 (1977-01-01), Partyka et al.
patent: 4001238 (1977-01-01), Partyka et al.
patent: 4039544 (1977-08-01), Broughton et al.
patent: 4060615 (1977-11-01), Matier et al.
patent: 4079057 (1978-03-01), Juby et al.
patent: 4098788 (1978-07-01), Crenshaw et al.
patent: 4101548 (1978-07-01), Crenshaw et al.
patent: 4102885 (1978-07-01), Crenshaw et al.
patent: 4138561 (1979-02-01), Crenshaw et al.
patent: 4146718 (1979-03-01), Jenks et al.
patent: 4161595 (1979-07-01), Kaplan et al.
patent: 4171363 (1979-10-01), Crenshaw et al.
patent: 4208521 (1980-06-01), Crenshaw et al.
patent: 4209623 (1980-06-01), Juby
patent: 4423075 (1983-12-01), Dvornik et al.
patent: 4460590 (1984-07-01), Moller
patent: 4460591 (1984-07-01), DeGraw et al.
patent: 4551529 (1985-11-01), Kern et al.
patent: 4880810 (1989-11-01), Lowe, III et al.
patent: 4885301 (1989-12-01), Coates
patent: 4923874 (1990-05-01), McMahon et al.
patent: 5073559 (1991-12-01), Coates
patent: 5147875 (1992-09-01), Coates et al.
patent: 5223501 (1993-06-01), Chakravarty et al.
patent: 5250535 (1993-10-01), Verheyden et al.
patent: 5254571 (1993-10-01), Coates et al.
patent: 5358952 (1994-10-01), Moschel et al.
patent: 5401774 (1995-03-01), Pamukcu et al.
patent: 5439895 (1995-08-01), Lee et al.
patent: 5488055 (1996-01-01), Kumar et al.
patent: 5614530 (1997-03-01), Kumar et al.
patent: 5614627 (1997-03-01), Takase et al.
patent: 5696159 (1997-12-01), Gross et al.
Blaya, C. et al., Effect of the protein kinase inhibitors, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine H-7 and N-(2-[methylamino]ethyl)-5-isoquinoline-sulfonamide H-8 on Lewis lung carcinoma tumor progression, European Journal of Pharmacology, 354, pp. 99-104 (1998).
Chang, W. et al., Sulindac Sulfone Modulates the Expression and Cellular Localization of b-Catenin in Human Colon Carcinoma Cells, Digestive Disease Week, Apr. 1, 1999.
Earnest, D. et al., Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention, Journal of Cellular Biochemistry, Supplement 161:156-166 (1992).
Easwaran, V. et al., The Ubiquitin-Proteasome Pathway and Serine Kinase Activity Modulate Adenomatous Polyposis Coli Protein-mediated Regulation of .beta.-Catenin-Lymphocyte Enhancer-binding Factor Signaling, The Journal of Biological Chemistry, vol. 274, No. 23, pp. 16641-16645, Jun. 4, 1999.
Jiang, X. et al., Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells, Proc. Natl. Acad. USA, vol. 83, pp. 11236-11241, Oct. 1996.
Korinek, V. et al., Constitutive Transcriptional Activation by a .beta.-Catenin-Tcf Complex in APC.sup.-/- Colon Carcinoma, Science, vol. 275, pp. 1784-1786, Mar. 21, 1997.
Mahmoud, N. et al., Apc Gene Mutation is Associated with a Dominant-Negative Effect upon Intestinal Cell Migration, Cancer Research 57, pp. 5045-5050, Nov. 15, 1997.
Mahmoud, N. et al., Genotype-Phenotype Correlation in Murine Apc Mutation: Differences in Enterocyte Migration and Response to Sulindac, Cancer Research 59, pp. 353-359, Jan. 15, 1999.
Morin, P. et al., Activation of .beta.-Catenin-Tcf Signaling in Colon Cancer by Mutations in .beta.-Catenin or APC, Science, vol. 275, pp. 1787-1789, Mar. 21, 1997.
Peifer, M., .beta.-Catenin as Oncogene: The Smoking Gun, Science, vol. 275, pp. 1752-1753, Mar. 21, 1997.
Rubinfeld, B. et al., Stabilization of .beta.-Catenin by Genetic Defects in Melanoma Cell Lines, Science, vol. 275, pp. 1790-1792, Mar. 21, 1997.
Waddel, W.R. et al., Am. J. Surgery,. vol. 157, pp. 175-179, (Jan. 1989).
Gonzaga, R.A.F. et al., The Lancet, Mar. 30, 1985, p. 751.
Waddell, W.R. et al., J. Surg. Oncology, vol. 24, pp. 83-87 (1983).
Federation Proceedings (Mar./Apr. 1972) of the Federation of American Societies for Experimental Biology abstract Nos. 2044 and 2045.
Gilman, S.C. et al., Nonsteroidal Anti-inflammatory Drugs in Cancer Therapy, (circa 1985).
Brogden, R.N. et al., Drugs, vol. 16, pp. 97-114 (1978).
Hucker, H.B. et al., Drug Metabolism & Disposition, vol. 1, No. 6, pp. 721-736 (1973).
Shen, T.Y. et al., Chemical and Biological Studies on Indomethacin, Sulindac and Their Analogs, pp. 107-178 (circa 1975).
Duggan, D.E. et al., Clin. Pharm. & Therapeutics, vol. 21, No. 3, pp. 326-335 (1976).
Duggan, D.E. et al., J. Pharm. & Exper. Therap., vol. 201, No. 1, pp. 8-13 (1977).
Glavin, G.B. et al., Toxicology and Applied Pharmacology, vol. 83, pp. 386-389 (1986).
Moorghen, M. et al., Journal of Pathology, vol. 156, pp. 341-347 (1988).
Moorghen, M. et al., Acta Histochemica, Suppl.-Band XXIX, S. 195-199 (1990).
Bjarnason et al., Gastroenterology, vol. 94, No. 4, pp. 1070-1074 (Apr. 1988).
Badrieh, Y., et al., Chem. Ber., vol. 125, pp. 667-674 (1992).
Silvola, J. et al., Effects of nonsteroidal anti-inflammatory drugs on rat gastric mucosal phosphodiesterase activity, Agents and Actions, vol. 12.4, pp. 516-520 (1982).
Curtis-Prior, P.B. et al., Cyclic Nucleotide Phosphodiesterase Activity of Human Normal and Carcinomatous Lung Tissue, The Lancet, pp. 1225-1225 Dec. 4, 1976.
Pepin, P. et al., Effects of Sulindac and Oltipraz on the tumorigenicity of 4-(methylnitrosamino)1-(3-pyridyl)-1-Butanone in A/J mouse lung, Carcinogenesis, vol. 13, No. 3, pp. 341-348 (1992).
Nicholson, C.D. et al. Differential modulation of tissue function therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes, Trends Pharmacol. Sci. (TiPS), vol. 12, pp. 19-27 (1991).
Ahn, H.S. et al., Effects of Selective Inhibitors on Cyclic Nucleotide Phosphodiesterases of Rabbit Aorta, Biochemical Pharmacology, vol. 38, No. 19, pp. 3331-3339 (1989).
Luginer, C. et al., Selective Inhibition of Cyclic Nucleotide Phosphodiesterases of Human, Bovine and Rat Aorta, Biochem. Pharmacology, vol. 35, No. 10, pp. 1743-1751 (1986).
Turner, N.C. et al., Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium mitroprusside, Br. J. Pharmacol. vol. III, pp. 1047-1052 (1994).
Weishaar, R.E. et al., Multiple Molecular Forms of Cyclic Nucleotide Phosphodiesterase in Cardiac and Smooth Muscle and In Platelets, Biochem. Pharmacology, vol. 35, No. 5, pp. 787-800 (1986).
Murray, K.J. et al., Potential Use of Selective Phosphodiesterase Inhibitors in the Treatment of Asthma, New Drugs for Asthma Therapy, Birkhauser Verlag Basel, pp. 27-46 (1991).
Saeki, T. et al., Isolation of Cyclic Nucleotide Phosphodiesterase Isozymes From Pig Aorta, Biochem. Pharmacology, vol. 46, No. 5, pp. 833-839 (1993).
Turner, N.C. et al., Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in anaesthetized guinea-pig, Br. J. Pharmacol., vol. 111, 1198-1204 (1994).
Ferreira, S.H. et al., The molecular mechanism of action of peripheral morphone analgesia: stimulation of the cGMP system via nitric oxide release, European Journal of Pharmacology, 201 pp. 121-122 (1991).
Hidaka, H. et al., Selective Inhibitors of Three Forms of Cyclic Nucleotide Phosphodiesterase--Basic and Potential Clinical Applications, vol. 16, Advances in Cyclic Nucleotide and Protein Phosphorylation Research, pp. 245-259 (1984).
Tulshian, D. et al., Synthesis and Phosphodiesterase Actitivy of Carboxylic Acid Mimetics of Cyclic Guanosine 3",5"-Monophosphate, J. Med. Chem, vol. 36, 1210-1220 (1993).
Yasumoto, T. et al., Properties of Base-Substituted and Carboxyl-Esterified Analogues of Griseolic Acid, a Potent cAMP Phosphodiesterase Inhibitor, Biochemical Pharmacology, vol. 43, No. 10, pp. 2073
Pamukcu Rifat
Piazza Gary A.
Cell Pathways Inc.
Fonda Kathleen K.
Stevenson Robert W.
LandOfFree
Method for inhibiting neoplastic cells and related conditions by does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting neoplastic cells and related conditions by, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting neoplastic cells and related conditions by will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2100468